Seattle, WA -- (SBWIRE) -- 10/07/2019 -- Blood Stream Infection Testing Market - Global Forecast to 2026, by Product Type (Instruments, Reagents, and Others), by Technology (Conventional Testing and Non-Conventional Testing), by Test Type (Conventional Blood Culture Tests, PCR Method, Nucleic Acid Testing, Mass Spectroscopy, and Point-of-Care Testing), by End User (Hospitals, Independent Diagnostics Centers, and Others) - Size, Share, Trends, and Forecast 2019 - 2026

Bloodstream infection is a medical condition where any fungal or bacterial infection is detected in the blood and this is caused by penetration of bacteria into the bloodstream. The bacteria which causes such infection are detected by using bloodstream infection testing. Increasing population base rate could lower the level of hygiene level which may lead to the occurrence of various disease. According to the World Bank 2016 report, the population has reached up to 7.44 billion globally. This rising population leads to fuel the growth of the bloodstream infection testing market.

Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1727

Self-diagnosis of bloodstream infections is difficult as it has very common symptoms such as cold, chills, fever, diarrhea, vomiting. So, this requires a mandatory diagnosis of the infection which is expected to raise the market growth. Moreover, the bloodstream infection tester identify antibiotic resistance marker in bacteria and it also diagnose sepsis.

The global bloodstream infection testing market size was valued at US$ 3,758.7 million in 2017 and is expected to exhibit a CAGR of 8.4% over the forecast period (2019 – 2026).

Rising prevalence of dental infection, abdominal infection, and chronic diseases is projected to boost the bloodstream infection testing market growth

Continuous increasing population base rate and insufficient shelters are the prime factors spreading disease around the globe. Additionally, rising awareness regarding chronic diseases such as cancer, HIV, and pneumonia which require blood testing regularly is assumed to augment the market growth. Ongoing innovation, research, and development program, merger, and acquisitions among key players will further favor the market growth of bloodstream infection testing market.

Growing demand for advanced diagnostic tests along with the rising awareness regarding hygiene, unhealthy lifestyle and treatment are also presumed to propel market growth over forecast time.

On the flip side, strict rules and regulatory scenario associated with diagnostic procedures coupled with the high cost of diagnosis and lack of medical reimbursement is expected to limit the market growth of bloodstream infection testing.

North America held a leading position in the global bloodstream infection testing market

Based on the region, the global bloodstream infection testing market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America held the dominant position in the global bloodstream infection testing market in 2018, and this can be attributed to the rising preventive healthcare awareness and rapid adoption of innovative and advanced medical devices. Moreover, rising diagnosis rate and well-established healthcare infrastructure in this region is also expected to fuel the growth of the bloodstream infection testing market in North America.

At the same time, Asia Pacific is expected to experience higher growth over the forecast period, on the ground of high prevalence of chronic diseases in the region. The availability of a wide range of innovative products offering advanced solutions to patients at marginally lower costs is also assumed to propel the bloodstream infection testing market growth. For instance, in 2017, a group of researchers led by the National Cancer Center Japan (NCC), together with Toray Industries, Inc., developed a new method that could detect thirteen different cancer types with a single drop of blood.

Also, in 2017, Luminex Corporation announced that Japan's Central Social Insurance Medical Council approved to provide reimbursement for two VERIGENE assays: the gram-positive and negative blood culture test. This reimbursement is recommended by the Japanese Ministry of Health, Labor and Welfare. The VERIGENE system can detect pathogens from the bloodstream for various infectious diseases.

Read Summary Of Report Here : https://www.coherentmarketinsights.com/market-insight/blood-stream-infection-testing-market-1727

Major Players Profiled In the Report:

Major players operating in the bloodstream infection testing market include BioMérieux SA, Becton, Dickinson and Company, AB Sciex, IRIDICA, Abbot Laboratories, Cepheid Inc., C. R. Bard, Inc., F. Hoffmann-La Roche AG, Nanosphere, Dade Behring, AdvanDX, and Siemens Healthcare.

Detailed Segmentation:

Global Blood Stream Infection Testing Market, By Product Type:
Instruments
Reagents
Others

Global Blood Stream Infection Testing Market, By Technology:
Conventional Testing
Non-conventional Testing

Global Blood Stream Infection Testing Market, By Test Type:
Conventional Blood Culture Tests
PCR Method
Nucleic Acid Testing
Mass Spectroscopy
Point-of-Care Testing

Global Blood Stream Infection Testing Market, By End User:
Hospitals
Independent Diagnostics Centers
Others

Global Blood Stream Infection Testing Market, By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Buy Now This Report @ https://www.coherentmarketinsights.com/insight/buy-now/1727

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.